Nivolumab, Relatlimab

• SUPRAME - ACTengine® IMA203 vs. investigator’s choice of treatment in previously treated, unresectable or metastatic cutaneous melanoma Recruiting
  2024-517062-42-00 Phase III 3 countries Immatics US Inc.
• A Phase 1/2 Study of BMS-986482 Alone or Combination Therapy in Participants with Advanced Solid Tumors Recruiting
  2024-516602-28-00 Phase I (FiH) 8 countries Bristol-Myers Squibb Services Unlimited Company
• A Study to Compare Vusolimogene oderparepvec (VO) Plus Nivolumab With the Doctor's Choice of Treatment in People With Skin Cancer That has G… Recruiting
  2023-508612-29-00 Phase III 6 countries Replimune Inc.
• A Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy in Participants with Non-s… Recruiting
  2024-513682-40-01 Phase III 12 countries Bristol-Myers Squibb Services Unlimited Company
• Phase II study of Roginolisib in UM patients Recruiting
  2024-514333-37-00 Phase II 2 countries iOnctura SA
• A phase IB clinical trial on neoadjuvant and intraoperative intracranial administration of triple immune checkpoint blockade plus myeloid d… Recruiting
  2024-517842-33-01 Phase I (Other) 1 country UZ Brussel
• A Study of Subcutaneous Nivolumab + Relatlimab FDC in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY-127) Recruiting
  2022-500967-11-00 Phase III 11 countries Bristol-Myers Squibb Services Unlimited Company
• Immune-Related Rheumatological and neurological Adverse Events study. Recruiting
  2024-516631-27-00 Phase II 1 country Stichting Amsterdam UMC
• Pan tumor Roll Over Study Recruiting
  2023-506914-32-00 Phase II 10 countries Bristol-Myers Squibb Services Unlimited Company
• Phase II Study of Nivolumab (Group 1) and Nivolumab plus Relatlimab (Group 2) in Patients with Locally Advanced/ Metastatic Squamous Cell Ca… Recruiting
  2024-513637-20-00 Phase II 1 country Gemeinnutzige Salzburger Landes kliniken Betriebsgesellschaft mbH
• Patient Preference for Route of Administration with Intravenous Infusion Switch to Subcutaneous I-O Regimens in Melanoma Ended
  2023-504515-33-00 Phase II 3 countries Bristol-Myers Squibb Services Unlimited Company
• This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety tolerability, pharmacokinetics… Ended
  2023-510061-10-00 Phase I (Other) 7 countries Exelixis Inc.
• A Study of Relatlimab plus Nivolumab Versus Nivolumab Alone in Participants with Advanced Melanoma Ended
  2024-510913-13-00 Phase II/III 13 countries Bristol-Myers Squibb Services Unlimited Company
• A Study of Relatlimab-nivolumab Fixed-dose Combination versus Regorafenib or TAS-102 in Participants with Later-lines of Metastatic Colorect… Ended
  2023-503797-21-00 Phase III 10 countries Bristol Myers Squibb International Corporation
• Adjuvant Immunotherapy with Nivolumab + Relatlimab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III… Ended
  2023-507688-20-00 Phase III 13 countries Bristol Myers Squibb International Corporation
• Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors Ended
  2023-508067-70-00 Phase I/II 9 countries Bristol Myers Squibb International Corporation

Showing 1–16 of 16 trials